Tripla negatív emlőrák: vizsgálatok itt: Dánia
5 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Aarhus, Copenhagen, Odense
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - 3. fázisTaking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Aalborg, Aarhus N, Herlev, Odense C, Soenderborg, Vejle
- Életkor
- 18 év and over
- People
- 1530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - 1. fázisTaking peoplePhase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
- Where
- Odense C
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07261631 - 1. fázisTaking peopleA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Copenhagen Oe, Odense C
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00 - 1. fázisTaking peoplePhase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
- Where
- Odense C
- Életkor
- 18 év and over
- People
- 66 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07630961